News
-
ADmit Therapeutics presents the MAP-AD Test at the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026)
Barcelona (Spain), November 4, 2026. ADmit Therapeutics will participate in the Neurogenetics Conference organized by MANLAB within the framework of the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026). Dr. Carla Trapero will present the MAP-AD Test, the only regulatory-approved blood-based prognostic test (IVDR – EU 2017/746) that predicts progression to Alzheimer’s dementia in patients with mild…
-
Pioneering Precision Medicine for Alzheimer’s: ViaCare and ADmit Therapeutics Partner to Transform Patient-Centered Neurological Care
Barcelona (Spain), October 21, 2026. Faced with Alzheimer’s disease, a pathology that deeply affects not only those living with it, but also their families and loved ones, early clarity and personal, compassionate, and close orientation are essential. ViaCare, a leading comprehensive private medical center in Madrid belonging to the Viamed Salud Group, and ADmit Therapeutics, a Spanish biotechnology company…
-
ADmit Therapeutics Closes Strategic Agreement with HVD Life Sciences to Accelerate Commercial Expansion
Barcelona (Spain), September 15, 2026. ADmit Therapeutics, a biotechnology company specializing in innovative diagnostic solutions for neurodegenerative diseases, is pleased to announce a new collaboration with HVD Life Sciences, a recognized leader in the commercialization of in vitro diagnostic solutions across international markets. This agreement represents a key milestone in ADmit Therapeutics’ commercial expansion strategy. HVD Life Sciences‘ deep expertise…
-
ADmit Therapeutics Obtains CLIA Certification, Opening Doors to the U.S. Healthcare Market
Barcelona (Spain), December 4, 2025. ADmit Therapeutics today announced that it has obtained the CLIA (Clinical Laboratory Improvement Amendments) Certificate. This accreditation, granted by the US Centers for Medicare & Medicaid Services (CMS), confirms compliance with the most stringent standards for analytical quality and reliability. Obtaining CLIA certification is a crucial milestone that transforms ADmit Therapeutics into a…
-
ADmit Therapeutics Presents Innovation in Seville: The MAP-AD® Test and New Data on Alzheimer’s Prediction
The company will attend the SEN Annual Meeting with its MAP-AD® test, recently certified with the CE-IVDR mark, highlighting breakthroughs in early Alzheimer’s disease dementia prognosis. Barcelona (Spain), November 14, 2025 – ADmit Therapeutics, a leading company in the diagnosis of neurodegenerative diseases, has confirmed its participation in the upcoming Annual Meeting of the Spanish Society of Neurology…
-
ADmit Therapeutics to showcase European innovation at MEDICA 2025
Barcelona (Spain), November 13,2025. We are proud to announce that our company has been selected to participate in MEDICA 2025, taking place from 17–20 November 2025 in Düsseldorf, Germany. ADmit Therapeutis will be at the EIC Pavilion at Messe Düsseldorf – Hall 15, Booth 15B41. Our company is one of the 15 SMEs, start-ups, and…
